Vendor review
Qing Li Peptide reviews
Qing Li Peptide reviews from 363 independent lab tests (Retatrutide, Tirzepatide and GHK-Cu): grade A, purity and fill accuracy. Is Qing Li Peptide legit? See what its vials showed.
What the lab tests show
363 tests on record, newest first. Scores are purity divided by ten.
| Date | Product | Purity | Quantity | Identity | Certificate |
|---|---|---|---|---|---|
| Oct 9, 2026 | Retatrutide | 99.9 % | 19.99 mg of 20 mg (0 %) | Pass | View |
| Oct 6, 2026 | Tirzepatide | 99.9 % | 30.6 mg of 30 mg (2 %) | Pass | View |
| Sep 25, 2026 | Retatrutide | 99.9 % | 28.7 mg of 30 mg (-4 %) | Pass | View |
| Sep 25, 2026 | MOTS-c | 99.9 % | 44.4 mg of 40 mg (11 %) | Pass | View |
| Sep 25, 2026 | BPC-157 | 99.9 % | 10.4 mg of 10 mg (4 %) | Pass | View |
| Sep 25, 2026 | Ipamorelin | 99.9 % | 10.4 mg of 10 mg (4 %) | Pass | View |
| Sep 25, 2026 | Tesamorelin | 99.9 % | 9.9 mg of 10 mg (-1 %) | Pass | View |
| Sep 24, 2026 | Retatrutide | 99.9 % | 9.06 mg of 10 mg (-9 %) | Pass | View |
| Sep 23, 2026 | Retatrutide | 99.9 % | 13.9 mg of 15 mg (-7 %) | Pass | View |
| Sep 15, 2026 | Retatrutide | 99.9 % | 14 mg of 15 mg (-7 %) | Pass | View |
| Sep 15, 2026 | TB-500 | 10 mg | Fail | View | |
| Sep 15, 2026 | GHK-Cu | 98.5 % | 49.25 mg of 50 mg (-2 %) | Pass | View |
| Sep 9, 2026 | BPC-157 | 99.7 % | 10.6 mg of 10 mg (6 %) | Pass | View |
| Sep 4, 2026 | Sermorelin | 98 % | 9.07 mg of 10 mg (-9 %) | Pass | View |
| Sep 4, 2026 | PT-141 | 99.7 % | 11.3 mg of 10 mg (13 %) | Pass | View |
| Aug 28, 2026 | BPC-157 | 99.6 % | 11.5 mg of 10 mg (15 %) | Pass | View |
| Aug 25, 2026 | GHK-Cu | 99.7 % | 57.2 mg of 50 mg (14 %) | Pass | View |
| Aug 13, 2026 | Retatrutide | 99.9 % | 30.3 mg of 30 mg (1 %) | Pass | View |
| Aug 13, 2026 | Retatrutide | 99.9 % | 9.09 mg of 10 mg (-9 %) | Pass | View |
| Aug 12, 2026 | Tesamorelin | 99.9 % | 10.1 mg of 5 mg (102 %) | Pass | View |
| Aug 12, 2026 | CJC-1295 | 98.5 % | 5.38 mg of 5 mg (8 %) | Pass | View |
| Aug 9, 2026 | Retatrutide | 99.8 % | 20.5 mg of 20 mg (2 %) | Pass | View |
| Aug 9, 2026 | Tesamorelin | 99.6 % | 6.3 mg of 5 mg (26 %) | Pass | View |
| Aug 9, 2026 | GHK-Cu | 99.7 % | 53.7 mg of 50 mg (7 %) | Pass | View |
| Aug 5, 2026 | BPC-157 | 98.9 % | 9.65 mg of 10 mg (-3 %) | Pass | View |
| Aug 4, 2026 | MOTS-c | 99.2 % | 39.6 mg of 40 mg (-1 %) | Pass | View |
| Aug 4, 2026 | Retatrutide | 99.9 % | 17.1 mg of 15 mg (14 %) | Pass | View |
| Aug 3, 2026 | Retatrutide | 99.9 % | 17.9 mg of 20 mg (-11 %) | Pass | View |
| Jul 23, 2026 | Tesamorelin | 98.6 % | 6.28 mg of 10 mg (-37 %) | Pass | View |
| Jul 17, 2026 | MOTS-c | 98.4 % | 10.2 mg of 10 mg (2 %) | Pass | View |
| Jul 1, 2026 | Retatrutide | 99.9 % | 9.09 mg of 10 mg (-9 %) | Pass | View |
| Jun 24, 2026 | Retatrutide | 99.9 % | 8.92 mg of 10 mg (-11 %) | Pass | View |
| Jun 24, 2026 | BPC-157 | 20 mg | Fail | View | |
| Jun 23, 2026 | GHK-Cu | 99.8 % | 44.7 mg of 50 mg (-11 %) | Pass | View |
| Jun 17, 2026 | Retatrutide | 99.9 % | 62 mg of 60 mg (3 %) | Pass | View |
| Jun 17, 2026 | Retatrutide | 99.7 % | 11 mg of 10 mg (10 %) | Pass | View |
| Jun 17, 2026 | Tesamorelin | 99.6 % | 5.6 mg of 5 mg (12 %) | Pass | View |
| Jun 17, 2026 | Tirzepatide | 99.9 % | 11.2 mg of 10 mg (12 %) | Pass | View |
| Jun 8, 2026 | Retatrutide | 99.3 % | 9.9 mg of 10 mg (-1 %) | Pass | View |
| Jun 8, 2026 | GHK-Cu | 99.9 % | 54.3 mg of 50 mg (9 %) | Pass | View |
| Jun 8, 2026 | Tirzepatide | 99.7 % | 24.1 mg of 20 mg (21 %) | Pass | View |
| Jun 5, 2026 | Retatrutide | 99.9 % | 38.7 mg of 40 mg (-3 %) | Pass | View |
| Jun 5, 2026 | Tirzepatide | 99.6 % | 48.7 mg of 50 mg (-3 %) | Pass | View |
| Jun 2, 2026 | MOTS-c | 98 % | 40.3 mg of 40 mg (1 %) | Pass | View |
| Jun 2, 2026 | GHK-Cu | 99.9 % | 46.4 mg of 50 mg (-7 %) | Pass | View |
| May 27, 2026 | Retatrutide | 99.9 % | 12.4 mg of 10 mg (24 %) | Pass | View |
| May 27, 2026 | Tirzepatide | 99.9 % | 44.5 mg of 30 mg (48 %) | Pass | View |
| May 27, 2026 | Ipamorelin | 99.7 % | 13.1 mg of 10 mg (31 %) | Pass | View |
| May 27, 2026 | TB-500 | 95.7 % | 12.1 mg of 10 mg (21 %) | Pass | View |
| May 13, 2026 | GHK-Cu | 99.4 % | 39.1 mg of 50 mg (-22 %) | Pass | View |
| May 13, 2026 | CJC-1295 | 99.9 % | 5.56 mg of 5 mg (11 %) | Pass | View |
| May 6, 2026 | BPC-157 | 99.9 % | 10.3 mg of 10 mg (3 %) | Pass | View |
| May 6, 2026 | Ipamorelin | 99.9 % | 5.2 mg of 5 mg (4 %) | Pass | View |
| May 6, 2026 | TB-500 | 10 mg | Fail | View | |
| May 5, 2026 | Retatrutide | 99.9 % | 27.6 mg of 30 mg (-8 %) | Pass | View |
| May 5, 2026 | Retatrutide | 98.7 % | 10.4 mg of 10 mg (4 %) | Pass | View |
| Apr 30, 2026 | Retatrutide | 99.6 % | 9.9 mg of 10 mg (-1 %) | Pass | View |
| Apr 28, 2026 | Tesamorelin | 98 % | 7.4 mg of 10 mg (-26 %) | Pass | View |
| Apr 28, 2026 | MOTS-c | 98.6 % | 43.1 mg of 40 mg (8 %) | Pass | View |
| Apr 28, 2026 | Tirzepatide | 99.9 % | 28.9 mg of 40 mg (-28 %) | Pass | View |
What Qing Li Peptide sells
No current listings on record.
About Qing Li Peptide
Finnrick has tested 363 samples from Qing Li Peptide across 15 products.